Text Size

Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis (RA)

This study is not yet open for participant recruitment.
Verified March 2012 by Alliancells Bioscience Corporation Limited
Sponsor:
Information provided by (Responsible Party):
Alliancells Bioscience Corporation Limited
ClinicalTrials.gov Identifier:
NCT01547091
First received: February 22, 2012
Last updated: May 14, 2012
Last verified: March 2012
History of Changes
  Purpose

Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic inflammation in the synovial tissue. Rheumatoid arthritis will eventually result in the destruction of cartilage, bone and ligaments and joint deformity. The underlying hypothesis is that umbilical cord-derived mesenchymal stem cell (UC-MSCs) has anti-inflammatory effects and thus potentially alleviates the progression of rheumatoid arthritis. The study is to explore the safety and efficacy of UC-MSCs transplantation in treatment of rheumatoid arthritis.


Condition Intervention Phase
Rheumatoid Arthritis
 Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Trial of Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation for Rheumatoid Arthritis-Phase I/II

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alliancells Bioscience Corporation Limited:

Primary Outcome Measures:
  • Safety of MSC treatment. [ Time Frame: six months ] [ Designated as safety issue: Yes ]
    Adverse Events will be recorded in a patient or clinical investigation subject who administers MSC and will be evaulated a causal relationship with the treatment.


Secondary Outcome Measures:
  • RA Serology [ Time Frame: 1, 3 and 6 months ] [ Designated as safety issue: Yes ]
    Rheumatoid Factor, C-reactive protein

  • Disease Activity Score (DAS 28) Index Mean Change From Baseline [ Time Frame: 1, 3 and 6 months ] [ Designated as safety issue: Yes ]
  • Patient's assessment of pain. [ Time Frame: 1, 3 and 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 150
Study Start Date: July 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: UC-MSCs Treatment
Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously.
 Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)
-The UC-MSCs will be infused intravenously(single dose, 10^7 cells)

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients fulfilled the classification criteria (2010) for rheumatoid arthritis, man or woman aged from 18 to 70 years old.
  • Patients must be informed of the investigational nature of this study and give written informed consent in accordance with the institutional and hospital guidelines.
  • Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on this trial. Women of child-bearing potential must have a pregnancy test performed within 72 hours prior to initiation of treatment.

Exclusion Criteria:

  • Any history of ongoing, significant or recurring infections.
  • Any active inflammatory diseases other than RA.
  • Significant cardiac or pulmonary disease.
  • End-stage renal failure.
  • Pregnant or nursing women may not participate due to the possibility of fetal harm or harm to nursing infants from this treatment regimen.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01547091

Contacts
Contact: Mingyuan Wu, MD,PhD 86-10-63188123 mingyuan-wu@ouhsc.edu
Contact: Haijie Ji, MD 86-10-63188853 jihaijie82@sohu.com

Locations
China, Shaanxi
The 323 Hospital of Chinese People's Liberation Army Not yet recruiting
Xi'an, Shaanxi, China, 710054
Contact: Liming Wang, MD     86-29-84756502     wanglm@fmmu.edu.cn    
Principal Investigator: Liming Wang, MD            
Sponsors and Collaborators
Alliancells Bioscience Corporation Limited
Investigators
Principal Investigator: Mingyuan Wu, MD,PhD Eastern Union Stem Cell & Gene Engineering Co.,Ltd，Alliancells Biosciences Co., Ltd
Principal Investigator: Yongjun Liu, MD,PhD Alliancells Biosciences Co., Ltd
Study Director: Liming Wang, MD The 323 Hospital of Chinese People's Liberation Army
Principal Investigator: Haijie Ji, MD Alliancells Biosciences Co., Ltd.
  More Information

No publications provided

Responsible Party: Alliancells Bioscience Corporation Limited
ClinicalTrials.gov Identifier: NCT01547091     History of Changes
Other Study ID Numbers: Alliancells-1
Study First Received: February 22, 2012
Last Updated: May 14, 2012
Health Authority: China: Ethics Committee

Keywords provided by Alliancells Bioscience Corporation Limited:
Mesenchymal Stem Cells
Rheumatoid Arthritis

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
 Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013